Even though the impact of obesity on the effectiveness of TCZ in RA remains controversial (63), the response to this drug is not significantly affected by weight or BMI, contrary to other biologic therapies, such as TNF inhibitors, making it a viable treatment option for overweight or obese RA patients (64, 65). This evidence concerns the gene TNF and Obesity.